% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Apr 27, 2013 8:52 PM Flag

    Match made in heaven -- DACLATASVIR and VX-135

    Gilead's sofosbuvir and Bristol’s daclatasvir [=BMS-790052] could make a happiest couple in the world if Gilead did allow sofosbuvir to wed daclatasvir. Read today's PR. But, Gilead said the dowry is too expensive and prefers a home-grown boy NS5A inhibitor. So, Bristol decided to screen VX-135 as a potential mate for daclatasvir. I have a hunch that VX-135 is as safe if not safer, and as potent, as sofosbuvir.

    There is a good reason to believe that inhibitors of NS5A and NS5B work together very well. A NS5A inhibitor is not just the disruptor of HCV replication complex. Just as protease inhibitors (like incivek) disrupt HCV's ability to evade host's immune response, NS5A inhibitors can also foil HCV's attempt to sabotage host's immunity, but in an independent pathway from protease inhibitors.

    Successes of all-oral HCV's non-structural protein inhibitors validate the concept that the currently developed DAAs have the immunological mechanism components, so that they can effectively replace interferon and ribavirin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
75.44-3.27(-4.15%)2:57 PMEDT